Healthcare - Biotechnology - NASDAQ - US
$ 2.427
-4.45 %
$ 2.93 M
Market Cap
-0.5
P/E
CASH FLOW STATEMENT
-3.15 M
OPERATING CASH FLOW
-14.4 K
INVESTING CASH FLOW
1.34 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Lipella Pharmaceuticals Inc.
| Net Income | -4.62 M |
| Depreciation & Amortization | 1.68 K |
| Capital Expenditures | -14.4 K |
| Stock-Based Compensation | 1.36 M |
| Change in Working Capital | -9.11 K |
| Others | 358 K |
| Free Cash Flow | -3.16 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (4.6) | (2.6) | (1.9) | 61.7 K | 61.8 K |
| Depreciation & Amortization | 1.68 K | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 1.4 | 0.7 | 0.7 | 57.7 K | 0 |
| Other Operating Activities | 0.1 | 9.61 K | 50.2 K | 7.64 K | 18.7 K |
| Change in Working Capital | 9.11 K | 9.52 K | 0.2 | 32.3 K | 14.3 K |
| Cash From Operations | (3.2) | (1.8) | (1.0) | 28.6 K | 39.1 K |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | 14.4 K | 0 | 0 | 0 | 0 |
| Other Items | 0 | 0.3 | (0.3) | 0 | 0 |
| Cash From Investing Activities | 14.4 K | 0.3 | (0.3) | 0 | 0 |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0.3 | 0 | 57 K | 25 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.3 | 0 | 0 | 0 | 0 |
| Cash From Financing Activities | 1.3 | 5.2 | 2.1 | 0.6 | 25 K |
| CHANGE IN CASH | |||||
| Net Change In Cash | (1.8) | 3.7 | 0.8 | 0.6 | 14.1 K |
| FREE CASH FLOW | |||||
| Free Cash Flow | (3.2) | (1.8) | (1.0) | 28.6 K | 39.1 K |